Dalotuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IGF-1 receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ECHA InfoCard | 100.205.569 |
| Chemical and physical data | |
| Formula | C6528H10086N1730O2018S40 |
| Molar mass | 146374.99 g·mol−1 |
| (what is this?) (verify) | |
Dalotuzumab is an anti-IGF1 receptor (IGF1R) humanized monoclonal antibody designed for the potential treatment of various cancers.[1] Common adverse effects include hyperglycemia, nausea, vomiting, and fatigue.[2] Dalotuzumab was developed by Merck and Co., Inc.[3]
- ^ Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S (June 2010). "Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer". Current Opinion in Molecular Therapeutics. 12 (3): 361–371. PMID 20521225.
- ^ Ma H, Zhang T, Shen H, Cao H, Du J (June 2014). "The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy". British Journal of Clinical Pharmacology. 77 (6): 917–928. doi:10.1111/bcp.12228. PMC 4093917. PMID 24033707.
- ^ "Dalotuzumab Overview". Creative Biolabs. Retrieved 2023-01-01.